Hakim Djaballah

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint An interview with Hakim Djaballah, Ph.D. Interview by Vicki Glaser
    Hakim Djaballah
    High Throughput Screening Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Assay Drug Dev Technol 8:519-25. 2010
  2. ncbi request reprint Editorial: from perfume oils to discovering and making new molecules: an international chemical biology journey
    Hakim Djaballah
    HTS Core Facility Memorial Sloan Kettering Cancer Center 1275 York Avenue New York 10065 USA
    Comb Chem High Throughput Screen 17:565. 2014
  3. pmc Chemical & RNAi screening at MSKCC: a collaborative platform to discover & repurpose drugs to fight disease
    Bhavneet Bhinder
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Comb Chem High Throughput Screen 17:298-318. 2014
  4. pmc Comparative analysis of RNAi screening technologies at genome-scale reveals an inherent processing inefficiency of the plasmid-based shRNA hairpin
    Bhavneet Bhinder
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Comb Chem High Throughput Screen 17:98-113. 2014
  5. pmc A high content assay to assess cellular fitness
    Christophe Antczak
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Comb Chem High Throughput Screen 17:12-24. 2014
  6. pmc Modulators of the microRNA biogenesis pathway via arrayed lentiviral enabled RNAi screening for drug and biomarker discovery
    David Shum
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
    Comb Chem High Throughput Screen 16:791-805. 2013
  7. pmc Systematic analysis of RNAi reports identifies dismal commonality at gene-level and reveals an unprecedented enrichment in pooled shRNA screens
    Bhavneet Bhinder
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, USA
    Comb Chem High Throughput Screen 16:665-81. 2013
  8. pmc An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates
    Bhavneet Bhinder
    High Throughput Screening Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Assay Drug Dev Technol 11:173-90. 2013
  9. pmc Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase
    Christophe Antczak
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bioorg Med Chem Lett 21:4528-32. 2011
  10. pmc An arrayed RNA interference genome-wide screen identifies candidate genes involved in the MicroRNA 21 biogenesis pathway
    David Shum
    High Throughput Screening Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Assay Drug Dev Technol 11:191-205. 2013

Research Grants

Collaborators

Detail Information

Publications51

  1. doi request reprint An interview with Hakim Djaballah, Ph.D. Interview by Vicki Glaser
    Hakim Djaballah
    High Throughput Screening Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Assay Drug Dev Technol 8:519-25. 2010
    Dr. Hakim Djaballah is Director of the High-Throughput Screening (HTS) Core Facility at Memorial Sloan-Kettering Cancer Center (MSKCC), in New York City...
  2. ncbi request reprint Editorial: from perfume oils to discovering and making new molecules: an international chemical biology journey
    Hakim Djaballah
    HTS Core Facility Memorial Sloan Kettering Cancer Center 1275 York Avenue New York 10065 USA
    Comb Chem High Throughput Screen 17:565. 2014
    ..In all, this issue contains research efforts from six countries and three continents: India, Iran, Poland, Serbia, Switzerland, and USA. ..
  3. pmc Chemical & RNAi screening at MSKCC: a collaborative platform to discover & repurpose drugs to fight disease
    Bhavneet Bhinder
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Comb Chem High Throughput Screen 17:298-318. 2014
    ....
  4. pmc Comparative analysis of RNAi screening technologies at genome-scale reveals an inherent processing inefficiency of the plasmid-based shRNA hairpin
    Bhavneet Bhinder
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Comb Chem High Throughput Screen 17:98-113. 2014
    ....
  5. pmc A high content assay to assess cellular fitness
    Christophe Antczak
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Comb Chem High Throughput Screen 17:12-24. 2014
    ..In summary, we report on a high content assay method to assess cellular overall fitness upon chemical transfection. ..
  6. pmc Modulators of the microRNA biogenesis pathway via arrayed lentiviral enabled RNAi screening for drug and biomarker discovery
    David Shum
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
    Comb Chem High Throughput Screen 16:791-805. 2013
    ..In summary, we report on 22 high confidence gene candidate regulators of miRNA biogenesis with potential use in drug and biomarker discovery. ..
  7. pmc Systematic analysis of RNAi reports identifies dismal commonality at gene-level and reveals an unprecedented enrichment in pooled shRNA screens
    Bhavneet Bhinder
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, USA
    Comb Chem High Throughput Screen 16:665-81. 2013
    ..Finally, we also would like to caution interpretation of pooled shRNA screening outcomes. ..
  8. pmc An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates
    Bhavneet Bhinder
    High Throughput Screening Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Assay Drug Dev Technol 11:173-90. 2013
    ....
  9. pmc Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase
    Christophe Antczak
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bioorg Med Chem Lett 21:4528-32. 2011
    ..Our results demonstrate that selective HsPDF inhibitors based on the benzofuran-4,5-dione scaffold constitute a novel class of antitumor agents that are potent in vitro and in vivo...
  10. pmc An arrayed RNA interference genome-wide screen identifies candidate genes involved in the MicroRNA 21 biogenesis pathway
    David Shum
    High Throughput Screening Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Assay Drug Dev Technol 11:191-205. 2013
    ..Altogether, our screen has uncovered a number of novel candidate regulators that are potentially good druggable targets allowing for the discovery and development of small molecules for regulating miRNA function...
  11. pmc Live-cell imaging of caspase activation for high-content screening
    Christophe Antczak
    High Throughput Screening Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Biomol Screen 14:956-69. 2009
    ....
  12. pmc A synergetic screening approach with companion effector for combination therapy: application to retinoblastoma
    Jeni P Mahida
    HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 8:e59156. 2013
    ..Our results validate this alternative approach, and we expect that our companion effector strategy could significantly impact both drug discovery and the nutraceutical industry...
  13. pmc An image-based biosensor assay strategy to screen for modulators of the microRNA 21 biogenesis pathway
    David Shum
    HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Comb Chem High Throughput Screen 15:529-41. 2012
    ..09%. Taken together, this validated strategy offers the opportunity to discover novel and specific inhibitors of the pathway through the screening of diverse chemical libraries...
  14. pmc Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors
    Christophe Antczak
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA
    Bioorg Med Chem Lett 19:6872-6. 2009
    ..Altogether, our results provide an insight into the SAR of pyrido[2,3-d]pyrimidin-7-ones for the development of drug candidates with improved potency and selectivity for the targeted treatment of CML...
  15. pmc A high throughput scintillation proximity imaging assay for protein methyltransferases
    Glorymar Ibáñez
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Cener, New York, NY 10065, USA
    Comb Chem High Throughput Screen 15:359-71. 2012
    ..The specific PMT inhibitors may constitute a new class of anti-proliferative agents for potential therapeutic use...
  16. pmc A high-throughput scintillation proximity-based assay for human DNA ligase IV
    Hui Min Tseng
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10583, USA
    Assay Drug Dev Technol 10:235-49. 2012
    ..The ability to screen and identify Lig4 inhibitors suggests that they may have utility as chemo- and radio-sensitizers in combination therapy and provides a rationale for using this screening strategy to identify additional inhibitors...
  17. pmc A miniaturized 1536-well format gamma-secretase assay
    Christopher C Shelton
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Assay Drug Dev Technol 7:461-70. 2009
    ..This validated assay can readily be used for primary screening against large chemical libraries searching for novel inhibitors of gamma-secretase activity that may represent potential therapeutics for AD and a variety of neoplasms...
  18. pmc Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein
    Rachel Kobos
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA
    J Pathol 229:743-54. 2013
    ..More generally, this work establishes a combined integrated genomics/functional genomics strategy to dissect the biology of oncogenic, chimeric transcription factors...
  19. pmc Comparison of luminescence ADP production assay and radiometric scintillation proximity assay for Cdc7 kinase
    Toshimitsu Takagi
    HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Comb Chem High Throughput Screen 14:669-87. 2011
    ..This report demonstrates the strong impact in detection format on the success of a screening campaign and the importance of carefully designed confirmatory assays to eliminate those compounds that target the detection part of the assay...
  20. pmc Development and validation of a high-density fluorescence polarization-based assay for the trypanosoma RNA triphosphatase TbCet1
    Christophe Antczak
    High Throughput Screening Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Comb Chem High Throughput Screen 12:258-68. 2009
    ..We present and discuss our findings and their importance for the discovery of novel drugs by high throughput screening...
  21. pmc Validation of a high-content screening assay using whole-well imaging of transformed phenotypes
    Christina N Ramirez
    Molecular Pharmacology and Chemistry Program, HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, USA
    Assay Drug Dev Technol 9:247-61. 2011
    ....
  22. pmc Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines
    Romel Somwar
    High Throughput Screening Core Facility, and Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA or
    Proc Natl Acad Sci U S A 108:16375-80. 2011
    ..These results suggest that SOD1 is an LCS-1-binding protein that may act in concert with mutant proteins, such as EGFR and KRAS, to promote cell growth, providing a therapeutic target for compounds like LCS-1...
  23. pmc Small-molecule inhibitors of SETD8 with cellular activity
    Gil Blum
    Molecular Pharmacology and Chemistry Program, Tri Institutional Training Program in Chemical Biology, and HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
    ACS Chem Biol 9:2471-8. 2014
    ..The commonality of SPS8I1-3 against SETD8, together with their distinct structures and mechanisms for SETD8 inhibition, argues for the collective application of these compounds as SETD8 inhibitors. ..
  24. pmc A 1536-well fluorescence polarization assay to screen for modulators of the MUSASHI family of RNA-binding proteins
    Gerard Minuesa
    Michael G Kharas Molecular Pharmacology and Chemistry Program, MSKCC, New York, USA
    Comb Chem High Throughput Screen 17:596-609. 2014
    ..In summary, we have developed an in vitro strategy to identify MSI specific inhibitors using an FP HTS platform, which will facilitate novel drug discovery for this class of RBPs. ..
  25. pmc A class of allosteric caspase inhibitors identified by high-throughput screening
    Taya Feldman
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Cell 47:585-95. 2012
    ..Based on these kinetic, biochemical, and structural analyses, we suggest that these compounds are allosteric caspase inhibitors that function through binding to the dimerization interface of caspases...
  26. pmc A high density assay format for the detection of novel cytotoxic agents in large chemical libraries
    David Shum
    High Throughput Screening Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Enzyme Inhib Med Chem 23:931-45. 2008
    ..It could potentially provide a rapid way to screen established and primary tumor cell lines against large chemical libraries...
  27. pmc Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells
    Romel Somwar
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Biomol Screen 14:1176-84. 2009
    ..Identification of the targets of LCS-1 and other growth inhibitors found in this screen may help to develop new agents for the treatment of lung adenocarcinomas, including those driven by mutant EGFR and KRAS...
  28. pmc A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery
    Christophe Antczak
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Biomol Screen 17:885-99. 2012
    ..Taken together, our results validate this novel approach and demonstrate its utility in the discovery of novel kinase modulators with potential use in the clinic...
  29. pmc High-content assay to identify inhibitors of dengue virus infection
    David Shum
    HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Assay Drug Dev Technol 8:553-70. 2010
    ..In summary, this assay offers the opportunity to screen libraries of chemical compounds, in an effort to identify and develop novel drug candidates against DENV infections...
  30. doi request reprint Intra-arterial and oral digoxin therapy for retinoblastoma
    Mrinali Patel
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA
    Ophthalmic Genet 32:147-50. 2011
    ..Preclinical studies demonstrate that cardiac glycosides such as ouabain and digoxin have antitumor effects on retinoblastoma cells in vitro and in a xenograft murine model of retinoblastoma...
  31. pmc A profiling platform for the identification of selective metalloprotease inhibitors
    Christophe Antczak
    High Throughput Screening Core Facility Molecular Pharmacology and Chemistry Program Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York 10065, USA
    J Biomol Screen 13:285-94. 2008
    ..The authors conclude that their profiling platform provides a generic assay solution for the identification of novel metalloprotease inhibitors as well as their selectivity profiling using a simple and homogeneous assay...
  32. pmc Discovery of a dicer-independent, cell-type dependent alternate targeting sequence generator: implications in gene silencing & pooled RNAi screens
    Bhavneet Bhinder
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 9:e100676. 2014
    ....
  33. pmc Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression
    Gabsang Lee
    Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, New York, USA
    Nat Biotechnol 30:1244-8. 2012
    ..Our data implicate alpha-2 adrenergic receptor activity in regulating IKBKAP expression and demonstrate that small-molecule discovery using an iPSC-based disease model can identify candidate drugs for potential therapeutic intervention...
  34. pmc A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells
    Christophe Antczak
    1 High Throughput Screening Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
    Assay Drug Dev Technol 12:28-42. 2014
    ....
  35. pmc Domain-based biosensor assay to screen for epidermal growth factor receptor modulators in live cells
    Christophe Antczak
    HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Assay Drug Dev Technol 10:24-36. 2012
    ..Gefitinib and PD 153035 were identified as hits in a pilot screen. This approach allows for the identification of novel EGFR modulators in high-throughput formats for screening chemical and RNAi libraries...
  36. pmc A novel high throughput 1536-well Notch1 γ -secretase AlphaLISA assay
    De Ming Chau
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Comb Chem High Throughput Screen 16:415-24. 2013
    ....
  37. pmc Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion
    Ji Zhang
    Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Cell 56:205-18. 2014
    ..Coupled with the success of L-asparaginase as a therapy for childhood leukemia, the data suggest that intracellular asparagine is a critical suppressor of apoptosis in many human tumors...
  38. pmc Designs and concept reliance of a fully automated high-content screening platform
    Constantin Radu
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Lab Autom 17:359-69. 2012
    ..The resulting system, referred to as Hestia, has been fully operational since the new year, has an onboard capacity of 504 plates, and harbors the only fully automated alpha INCA3000 unit in the world...
  39. pmc Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of cardenolides
    Christophe Antczak
    High Throughput Screening Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Invest Ophthalmol Vis Sci 50:3065-73. 2009
    ..It allows local delivery of relatively high doses of chemotherapy agents while bypassing general blood circulation. For this reason, this study was undertaken to revisit some of the FDA-approved drugs for the treatment of retinoblastoma...
  40. doi request reprint Azaphilones from an Acid Mine Extremophile Strain of a Pleurostomophora sp
    Andrea A Stierle
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
    J Nat Prod 78:2917-23. 2015
    ..1 μM), leukemia cell lines CCRF-CEM and SR, and the melanoma cell line LOX IMVI (IC50 = 10 μM). ..
  41. doi request reprint A High-Content Assay to Screen for Modulators of EGFR Function
    Christophe Antczak
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Methods Mol Biol 1360:97-106. 2016
    ..This method can readily be used to search for EGFR modulators in both chemical and RNAi screening; with potential applicability to other receptor tyrosine kinases. ..
  42. pmc Plasmid-based shRNA lentiviral particle production for RNAi applications
    David Shum
    HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Biomol Screen 19:1309-13. 2014
    ..We present the complete optimized workflow and demonstrate this utility in which a single modification of this transfection step improved the lentiviral particle production. ..
  43. ncbi request reprint Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib
    Darren R Veach
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Med Chem 50:5853-7. 2007
    ..Compound 5 potently inhibits Abl, Src, and Kit kinases and inhibits K562 and M07e/p210bcr-abl human leukemic cell growth. Using positron emission tomography, we visualized K562 tumor xenografts in mice with [18F]-5...
  44. pmc Modulation of gamma-secretase specificity using small molecule allosteric inhibitors
    Christopher C Shelton
    Molecular Pharmacology and Chemistry Program and High Throughput Screening Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 106:20228-33. 2009
    ..Furthermore, this class of selective inhibitors provides the basis for development of Alzheimer disease therapeutic agents...
  45. pmc A simple method for analyzing actives in random RNAi screens: introducing the "H Score" for hit nomination & gene prioritization
    Bhavneet Bhinder
    HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, USA
    Comb Chem High Throughput Screen 15:686-704. 2012
    ..The H score provides a very useful tool for stringent active gene nomination, gene list comparison across multiple studies, prioritization of hits, and evaluation of the quality of the nominated gene hits...
  46. pmc Cell viability assessment: toward content-rich platforms
    Christina Nicole Ramirez
    HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA
    Expert Opin Drug Discov 5:223-33. 2010
    ..The use of such content-rich platforms is a necessity to predict the toxicology of drug candidates accurately...
  47. pmc High-throughput identification of inhibitors of human mitochondrial peptide deformylase
    Christophe Antczak
    High Throughput Screening Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Biomol Screen 12:521-35. 2007
    ....
  48. pmc High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells
    Sabrina C Desbordes
    Developmental Biology Program, Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cell Stem Cell 2:602-12. 2008
    ..The availability of high-content assays should accelerate progress in basic and translational hESC biology...
  49. pmc A high-throughput screen for alpha particle radiation protectants
    Jonathan H Seideman
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Assay Drug Dev Technol 8:602-14. 2010
    ..Further application of the described assay could yield compounds useful in minimizing the toxicity and carcinogenesis associated with alpha particle exposure...
  50. ncbi request reprint Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors
    Darren R Veach
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nucl Med Biol 32:313-21. 2005
    ..8-fold uptake selectivity for the Bcr-Abl-expressing K562 cells at 60 min. These results suggest that pyridopyrimidinone radiotracers may be useful in imaging Abl-, Bcr-Abl- or Src-expressing malignancies...
  51. pmc Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly
    Liang Deng
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Virol 81:13392-402. 2007
    ..Despite its favorable activity in cell culture, mitoxantrone administered intraperitoneally at the maximum tolerated dose failed to protect mice against a lethal intranasal infection with vaccinia virus...

Research Grants1

  1. Novel & Selective Small Molecular Inhibitors of Human Peptide Deformylase
    Hakim Djaballah; Fiscal Year: 2006
    ..Indeed, the likelihood that a compound interferes with both assays, and therefore behaves as a false positive in both assays, is vastly reduced compared to a strategy solely based on one technique. ..